Experimental: Dose Level -1
Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
Drug: Neratinib 160 mg
Escalating doses to determine recommended phase 2 dose (RP2D)
Drug: Niraparib 100 mg
Escalating doses to determine recommended phase 2 dose (RP2D)
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
